Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Linagliptin on Myocardial Diastolic Function in Type 2 Diabetes Mellitus
2012-003858-81Phase 3Terminated
- Sponsor
- RWTH Aachen University Faculty of Medicine
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), heart failure with preserved ejection fraction (HFpEF) and left ventricular diastolic dysfunction (LVDD) comparing Linagliptin 5 mg qd with Placebo qd (2 arms). Primary endpoint: Change in left ventricular diastolic function. Started Apr 2013; status: terminated.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure with preserved ejection fraction (HFpEF)left ventricular diastolic dysfunction (LVDD)
Beyond the preview
Go deeper on 2012-003858-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003858-81.